News

The microbiome diversity in the lungs of cystic fibrosis (CF) patients increased after treatment with Trikafta, becoming similar to a person without CF, an analysis showed. In addition, small molecule metabolites produced by cells varied widely across patients while on the therapy, with the largest decrease seen in…

For the first time, many features of cystic fibrosis (CF) were modeled accurately in a human Lung Airway Chip lined with cells from CF patients, which included enhanced mucus secretion, inflammation, and microbial infections, a study has shown. This “organ-on-a-chip model” of the disease may support the rapid development…

Large-scale clinical trials and other research are “urgently required” to determine the best ways to manage the growing number of infections with nontuberculous mycobacteria — known as NTM — among children with cystic fibrosis (CF). That’s the argument made by a team of scientists in the U.K., in the…

Eloxx Pharmaceuticals’ experimental therapy ELX-02 was generally safe and resulted in a significant reduction in sweat chloride levels — a biomarker of cystic fibrosis (CF) — in patients carrying the most common CF-causing nonsense mutation, according to top-line data from a Phase 2 clinical program. While the short…

Molecules produced by the environmental bacteria Pseudomonas aeruginosa, called alkyl-quinolones derivatives — which regulate bacterial gene activity and act in cell-to-cell communication — may be useful markers for better management of patients with cystic fibrosis (CF), a study suggests. These derivatives also may enable a more clear definition…

Note: This story was updated Nov. 18, 2021, to correct information about Pulmozyme’s administration method. Bronchitol (mannitol) plus Pulmozyme (dornase alfa) is better than Pulmozyme alone to help loosen mucus in the lungs in children with cystic fibrosis (CF), and this seems to translate into better lung function. The…

A branch of the European Medicines Agency (EMA) has recommended expanding Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to include children with cystic fibrosis (CF) as young as age 6 who have at least one F508del mutation. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP),…

People with cystic fibrosis (CF) who have mild depression or anxiety report heightened stress, with significantly lower scores on 10 of 12 measures of health-related life quality as compared with the general population of CF patients, new research shows.  According to…

Despite longer hospital stays and higher costs, adults with cystic fibrosis (CF) do not have a greater risk of death from surgery to remove the gallbladder — called a cholecystectomy — compared with people who do not have CF, a study reported. “Importantly, we found that cholecystectomy had very…

Elexacaftor (VX-445), a next-generation CFTR corrector that is part of the triple-combination therapy Trikafta, is also a potentiator, a study reports. Results further showed that in combination with ivacaftor, sold as Kalydeco and also a potentiator, elexacaftor boosts ion flow across CFTR, the…